奧賽康(002755.SZ):與上海藥明康德合作開發新藥並簽署合作開發合同書
格隆匯 3 月 18日丨奧賽康(002755.SZ)公佈,公司的子公司江蘇奧賽康藥業有限公司(“子公司”)與上海藥明康德新藥開發有限公司(“上海藥明康德”)於近日合作開發新藥並簽署《合作開發合同書》。
項目名稱:用於Exon14突變及第三代EGFR抑制劑耐藥性的NSCLC治療的一類新藥開發。
項目內容:按照中國國家藥品監督管理局(National Medical Products Administration,“NMPA”)的要求及相關法規的要求,完成治療Exon14突變及第三代EGFR抑制劑耐藥性的NSCLC的一類新藥研發項目的臨牀前候選化合物(PCC)和臨牀候選化合物(IND)的相關研究工作。
子公司按照合同約定方式分階段向上海藥明康德支付臨牀前研發費用、臨牀里程碑金以及上市銷售提成。合同臨牀前研發費用總額為人民幣4000萬元整。
合同的履行符合公司戰略發展目標的要求,腫瘤領域是本公司主要聚焦領域,尤其針對其中發病率最高的肺癌,已佈局系列產品。ASK120067是靶向作用於T790M的三代EGFR抑制劑,用於治療非小細胞肺癌。目前ASK120067獲得了國家藥品監督管理局藥品審評中心(CDE)許可,完成臨牀II期研究後可有條件批准,奧賽康目前已完成臨牀II期入組,預計2021年完成臨牀研究並向CDE申請上市。本次公司與上海藥明康德合作開發的創新藥項目,除用於Exon14突變的非小細胞肺癌,還將與公司三代EGFR抑制劑ASK120067聯合,用於一代EGFR抑制劑耐藥的T790M陰性患者,以及用於三代EGFR抑制劑耐藥的患者,進一步拓展非小細胞肺癌的目標人羣,使更多的患者獲益。該合作將有利於進一步完善公司抗腫瘤產品線,提高公司的競爭力和持續盈利能力,對公司的戰略布局起到積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.